The American Academy of Pediatrics (AAP) recommends that all children aged 6 months and older, without medical contraindications, receive the 2026-27 influenza vaccine as soon as it becomes available. This guidance aims to reduce pediatric hospitalizations and deaths, particularly as children face higher risks due to close proximity in school settings.
The push for widespread vaccination comes after a period of significant pediatric risk. According to reporting from CIDRAP, the 2025-26 flu season was considered severe, resulting in 190 children dying. Other data cited by HealthyChildren.org indicates that through June 21, 2025, the CDC reported 253 influenza-related pediatric deaths, with 42.7% occurring in children who did not have a high-risk medical condition.
AAP Vaccination Protocols and Dosage for Children
The AAP advises that any licensed vaccine appropriate for a child’s age and health status may be used, with no preference for one specific product or formulation. These options include recombinant influenza vaccine (RIV), live attenuated influenza vaccine (LAIV) delivered via nasal spray, and inactivated influenza vaccine (IIV).
For children between 6 months and 8 years old, the dosing schedule depends on their prior vaccination history.
Regarding other safety concerns, a CDC study noted a small increased risk for febrile seizures within 24 hours when the inactivated influenza vaccine is administered simultaneously with DTaP or PCV13 vaccines. Despite this, the ACIP still recommends giving these vaccines at the same visit if indicated, as the overall risk remains small.
Risk Factors and Pediatric Vulnerabilities
The stakes are highest for children under 5, who are especially vulnerable to death and hospitalization. Historically, up to 80% of influenza-associated pediatric deaths have occurred in children who were unvaccinated or incompletely vaccinated. In the 2025-26 season, CIDRAP reports that approximately 85% of flu deaths occurred in unvaccinated children.
The AAP’s recommendations extend to pregnant and breastfeeding women. Vaccination during pregnancy protects the newborn for the first six months of life through the transplacental passage of antibodies.
Vaccine Efficacy and Community Impact
Public health officials acknowledge that vaccine efficacy can vary. Because flu strains shift, the vaccine is not always an exact match for the strains circulating in a specific community. However, medical experts emphasize that the vaccine still provides protection against serious illness.
“Getting children vaccinated is like giving their immune system a book that teaches their bodies to recognize and resist a disease. Immunized kids are healthier kids who can focus on growing, playing and learning.”
Kristina Bryant, MD, FAAP, member of the AAP Committee on Infectious Diseases
Despite these recommendations, uptake remains stagnant. As of May 2026, only 49.4% of children ages 6 months to 17 years had received the flu vaccine, a rate similar to the previous year. This gap in coverage persists even as the potential for “twindemics” or “tripledemics” increases, where flu, COVID-19, and other viruses spread simultaneously.
The disconnect between the high severity of recent seasons—marked by hundreds of pediatric deaths—and the low vaccination rate suggests that clinical recommendations alone are not overcoming the barriers to pediatric immunization. With the AAP pushing for immediate vaccination as soon as the 2026-27 supply is available, the focus shifts to whether providers can close this gap before the October window for optimal protection closes.
Related reading
